Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine Zidovudine-Lamivudine-Efavirenz Antiretroviral Treatment (ART) Among HIV-1 Infected Children: Asella Teaching and Referral Hospital, South-East Ethiopia

Overview

Journal Open Med Inform J

Publisher Bentham Open

Specialty Medical Informatics

Date 2018 Jun 8

PMID 29875890

Citations 5

Authors

Abebe Sorsa

Affiliations

Soon will be listed here.

Abstract

Background: Antiretroviral Therapy(ART) remarkably reduced HIV-1 infection-related mortality in children. The efficacy and safety of different ART regimen in pediatric age groups remained issues of debates and available evidence were scarce especially among children taking the of one the two prototypes (NVP or EFV) Non-Nucleoside Reverse Transcriptase Inhibitor(NNRTI) as backbone of ART regimen.Therefore, the objective of this study was to compare clinical, immunological and virological responses of zidovudine-lamivudine-nevirapine (AZT+3TC+ NVP) zidovudine-lamivudine-efavirenz (AZT+3TC+EFV) ART regimen among HIV-1 infected children.

Methods: A retrospective cross-sectional study was done by reviewing medical records of the patients to evaluate clinical, immunological and virological outcomes of NVP+AZT+3TC EFV+AZT+3TC ART regimen among HIV-1 infected children. Data were entered into Epi-info version 7.2.2 for clean up and exported to SPSS version 17 for analysis. Paired and Independent t-tests were used to compare the CD4 cell count, weight and virologic level at six months with corresponding baseline value; and the mean weight, CD4 gain and viral suppression across the two ART regimens at six months of ART respectively.

Results: Medical records of 122 patients from NVP-based regimen and 61 patients from EFV group were reviewed. After six months of NVP+AZT+3TC treatment, the mean CD4 cell count difference from baseline was 215(95% CI, 175.414-245.613, p<0.001). From EFV+AZT+3TC group, the mean CD4 cell count difference from baseline was 205(95% CI 155.404-235.623, p< 0.001). The mean CD4 count difference between the two regimens was comparable (p 0.145). Similarly, optimal viral suppression was achieved in 82% (100/122) of NVP+AZT+3TC regimen and 83% (44/61) of EFV+AZT+3TC regimen which was still comparable across the two groups.

Conclusion: There was no difference in clinical, immunological and virological outcomes among patients taking NVP+AZT+3TC or EFV+AZT+3TC ART regimen.

Citing Articles

Virological Suppression and its Predictors Among HIV/AIDS Patients on Antiretroviral Therapy in Ethiopia: Systematic Review and Meta-analysis.

Melak D, Bayou F, Yasin H, Zerga A, Wagaye B, Yeshanew Ayele F Open Forum Infect Dis. 2024; 11(4):ofae168.

PMID: 38654969 PMC: 11036161. DOI: 10.1093/ofid/ofae168.

First line antiretroviral treatment failure and its association with drug substitution and sex among children in Ethiopia: systematic review and meta-analysis.

Masresha S, Alen G, Kidie A, Dessie A, Dejene T Sci Rep. 2022; 12(1):18294.

PMID: 36316358 PMC: 9622840. DOI: 10.1038/s41598-022-22237-6.

Treatment outcomes and characteristics of HIV-2 patients compared to HIV-1 patients on an NNRTI-based first line art at the adult infectious diseases centre of the University Teaching Hospital (UTH) in Lusaka.

Bhebhe A, Chongwe G, Moonga G Pan Afr Med J. 2022; 40:231.

PMID: 35178142 PMC: 8817188. DOI: 10.11604/pamj.2021.40.231.25149.

Predictors of Current CD4+ T-Cell Count Among Women of Reproductive Age on Antiretroviral Therapy in Public Hospitals, Southwest Ethiopia.

Belay A, Manaye G, Kebede K, Abateneh D HIV AIDS (Auckl). 2021; 13:667-679.

PMID: 34168505 PMC: 8216731. DOI: 10.2147/HIV.S294367.

Long-Term Immunological and Virological Outcomes in Children Receiving Highly Active Antiretroviral Therapy at Hawassa University College of Medicine and Health Sciences, Southern Ethiopia.

Fenta D, Wube T, Mohammed Nuru M J Immunol Res. 2021; 2021:2498025.

PMID: 33928167 PMC: 8053046. DOI: 10.1155/2021/2498025.

References

Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Kumar S, Iliayas S . Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis. 2011; 53(7):716-24. DOI: 10.1093/cid/cir447. View

Ayele T, Worku A, Kebede Y, Alemu K, Kasim A, Shkedy Z . Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies. Syst Rev. 2017; 6(1):173. PMC: 5574138. DOI: 10.1186/s13643-017-0567-7. View

Puthanakit T, Kerr S, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V . Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J. 2009; 28(6):488-92. DOI: 10.1097/inf.0b013e318194eea6. View

Gulick R, Ribaudo H, Shikuma C, Lustgarten S, Squires K, Meyer 3rd W . Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004; 350(18):1850-61. DOI: 10.1056/NEJMoa031772. View

Jiang H, Zhang M, Chen H, Yang Y, Deng M, Ruan B . Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2014; 25:130-5. DOI: 10.1016/j.ijid.2014.04.020. View

Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix M, Le Tiec C . Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis. 2009; 9:81. PMC: 2701435. DOI: 10.1186/1471-2334-9-81. View

Lopez de Castilla D, Verdonck K, Otero L, Iglesias D, Echevarria J, Lut L . Predictors of CD4+ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru. Int J Infect Dis. 2008; 12(3):325-31. DOI: 10.1016/j.ijid.2007.09.008. View

Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W . Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis. 2006; 43(2):253-5. DOI: 10.1086/505210. View

Shearer K, Brennan A, Maskew M, Long L, Berhanu R, Sanne I . The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. J Int AIDS Soc. 2014; 17:19065. PMC: 4215701. DOI: 10.7448/IAS.17.1.19065. View

10.

Ojha C, Shakya G, Dumre S . Virological and Immunological Status of the People Living with HIV/AIDS Undergoing ART Treatment in Nepal. Biomed Res Int. 2016; 2016:6817325. PMC: 4980499. DOI: 10.1155/2016/6817325. View

11.

Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W . Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. Int J Infect Dis. 2008; 12(6):e33-8. DOI: 10.1016/j.ijid.2007.10.008. View

12.

Zanoni B, Phungula T, Zanoni H, France H, Cook E, Feeney M . Predictors of poor CD4 and weight recovery in HIV-infected children initiating ART in South Africa. PLoS One. 2012; 7(3):e33611. PMC: 3306429. DOI: 10.1371/journal.pone.0033611. View

13.

Crum-Cianflone N, Roediger M, Eberly L, Ganesan A, Weintrob A, Johnson E . Impact of weight on immune cell counts among HIV-infected persons. Clin Vaccine Immunol. 2011; 18(6):940-6. PMC: 3122603. DOI: 10.1128/CVI.00020-11. View

14.

Zheng J, Zhao D . Clinical, immunological, and virological outcomes of pediatric antiretroviral therapy in central China. BMC Res Notes. 2014; 7:419. PMC: 4086285. DOI: 10.1186/1756-0500-7-419. View

15.

Sinha S, Gupta K, Tripathy S, Dhooria S, Ranjan S, Pandey R . Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study. BMC Infect Dis. 2017; 17(1):761. PMC: 5725946. DOI: 10.1186/s12879-017-2864-0. View

16.

Mwesigire D, Wu A, Martin F, Katamba A, Seeley J . Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study. BMC Health Serv Res. 2015; 15:292. PMC: 4517416. DOI: 10.1186/s12913-015-0959-0. View

17.

Kwofie T, Owusu M, Mutocheluh M, Nguah S, Obeng-Baah J, Hanson C . Pattern and predictors of immunologic recovery in HIV infected patients. BMC Res Notes. 2015; 8:413. PMC: 4560874. DOI: 10.1186/s13104-015-1406-3. View

18.

Cozzi-Lepri A, Phillips A, Monforte A, Piersantelli N, Orani A, Petrosillo N . Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis. 2002; 185(8):1062-9. DOI: 10.1086/339821. View

19.

van Leeuwen R, Katlama C, Murphy R, Squires K, Gatell J, Horban A . A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003; 17(7):987-99. DOI: 10.1097/00002030-200305020-00007. View